2 results
Approved WMOCompleted
To assess the bioequivalence of two marketed formulations of ribavirin (ribavirin solution and capsules).
Approved WMOCompleted
The primary objective of this study is to determine whether the Impella cVAD device vs. IABP therapy leads to a higher 30 day survival rate in shock STEMI patients in the setting of primary PCI.